Symptoms and General Pathology

All Conditions

Infections

Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Immune System Diseases

Rare Diseases

Syndrome

Sarcoma

Communicable Diseases

Acquired Immunodeficiency Syndrome

HIV Infections

Immunologic Deficiency Syndromes

Sarcoma, Kaposi

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Virus Diseases

Herpesviridae Infections

DNA Virus Infections

Neoplasms, Vascular Tissue

Soft Tissue Sarcoma

Tecogalan sodium

To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.

Patients receive intravenous DS-4152 by infusion once every 21 days; courses may repeat. Patients undergo weekly follow-up. A punch biopsy will be obtained from patients with Kaposi's sarcoma.

A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days

Daiichi Pharmaceuticals

Patients receive intravenous DS-4152 by infusion weekly for 4 weeks, followed by 2 weeks of rest; courses may repeat. Patients undergo weekly follow-up. A punch biopsy will be obtained from patients with Kaposi's sarcoma.

A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4

Patients receive intravenous DS-4152 by infusion twice weekly for 21 days, followed by 2 weeks of rest; courses may repeat. Patients undergo weekly follow-up. A punch biopsy will be obtained from patients with Kaposi's sarcoma.

A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.

A Study of Tecogalan Sodium

A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Twice Weekly for 21 Days

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days	NCT00002136	Sarcoma, Kaposi HIV Infections	Tecogalan sodiu...	18 Years -	NIH AIDS Clinical Trials Information Service
A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4	NCT00002137	Sarcoma, Kaposi HIV Infections	Tecogalan sodiu...	18 Years -	NIH AIDS Clinical Trials Information Service
A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4	NCT00002137	Sarcoma, Kaposi HIV Infections	Tecogalan sodiu...	18 Years -	NIH AIDS Clinical Trials Information Service
A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.	NCT00002138	Sarcoma, Kaposi HIV Infections	Tecogalan sodiu...	18 Years -	NIH AIDS Clinical Trials Information Service
A Study of Tecogalan Sodium	NCT00002342	Sarcoma, Kaposi HIV Infections	Tecogalan sodiu...	18 Years -	NIH AIDS Clinical Trials Information Service
A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.	NCT00002138	Sarcoma, Kaposi HIV Infections	Tecogalan sodiu...	18 Years -	NIH AIDS Clinical Trials Information Service
A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days	NCT00002136	Sarcoma, Kaposi HIV Infections	Tecogalan sodiu...	18 Years -	NIH AIDS Clinical Trials Information Service
A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.	NCT00002138	Sarcoma, Kaposi HIV Infections	Tecogalan sodiu...	18 Years -	NIH AIDS Clinical Trials Information Service
A Study of Tecogalan Sodium	NCT00002342	Sarcoma, Kaposi HIV Infections	Tecogalan sodiu...	18 Years -	NIH AIDS Clinical Trials Information Service

Spots Global Cancer Trial Database for tecogalan sodium